There are 1105 resources available
634P - Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo)
Presenter: Steven Kao
Session: Poster Display session
Resources:
Abstract
635P - Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC
Presenter: Byoung Chul Cho
Session: Poster Display session
Resources:
Abstract
636P - SKYSCRAPER-02C: Phase III study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC) in China
Presenter: Shun Lu
Session: Poster Display session
Resources:
Abstract
637P - Taletrectinib vs repotrectinib in ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)
Presenter: Misako Nagasaka
Session: Poster Display session
Resources:
Abstract
638P - Dacomitinib with or without dose titration in treatment naïve advanced EGFR mutated NSCLC: Primary analysis of the ATORG-003 phase II trial
Presenter: Aaron Tan
Session: Poster Display session
Resources:
Abstract
639P - A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-stage small cell lung cancer (WJOG13520L, REBORN trial)
Presenter: Motoko Tachihara
Session: Poster Display session
Resources:
Abstract
640P - Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation
Presenter: Byoung Chul Cho
Session: Poster Display session
Resources:
Abstract
641P - METRIX: International real-world study of c-Met protein overexpression in patients with non-small cell lung cancer
Presenter: Hidehito Horinouchi
Session: Poster Display session
Resources:
Abstract
642P - Phase II trial of lazertinib plus pemetrexed/carboplatin in patients with EGFR-mutant recurrent or metastatic non-small cell lung cancer who failed prior lazertinib (LUCAS): Interim analysis
Presenter: Min Hee Hong
Session: Poster Display session
Resources:
Abstract
643P - Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): Second interim analysis of ALCURE
Presenter: Atsuto Mouri
Session: Poster Display session
Resources:
Abstract